Get the Stockscreener App
13.06
3.58%
0.21
Greenwich Lifesciences Inc stock is traded at $13.06, with a volume of 2,053.
It is up +3.58% in the last 24 hours and down -0.60% over the past month.
Greenwich LifeSciences Inc is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. Its Product Candidates include; GP2, a HER2/neu transmembrane peptide that elicits a targeted immune response against HER2/neu-expressing cancers, GM-CSF Immunoadjuvant has been shown to enhance monocyte and neutrophil cytotoxicity against melanoma tumor cells and to enhance activity-dependent cellular cytotoxicity of monocytes and neutrophils against targets coated with the anti-ganglioside antibodies, and Cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells to inhibit the spread of cancer.
See More
Previous Close:
$12.85
Open:
$12.97
24h Volume:
2,053
Relative Volume:
0.07
Market Cap:
$168.05M
Revenue:
-
Net Income/Loss:
$-8.89M
P/E Ratio:
-18.66
EPS:
-0.7
Net Cash Flow:
$-6.48M
1W Performance:
-2.06%
1M Performance:
-0.60%
6M Performance:
-1.70%
1Y Performance:
+25.57%
1-Day Range:
$12.97
$13.44
1-Week Range:
$12.20
$14.31
52-Week Range:
$8.00
$21.44
Greenwich Lifesciences Inc Stock (GLSI) Company Profile
Name
Greenwich Lifesciences Inc
Sector
Industry
Phone
203-434-3290
Address
3992 BLUEBONNET DR, BUILDING 14, STAFFORD
Compare GLSI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| GLSI | 13.30 | 168.05M | 0 | -8.89M | -6.48M | -0.70 |
| VRTX | 446.42 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 739.53 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 587.24 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.68 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.48 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Greenwich Lifesciences Inc Stock (GLSI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-01-21 | Initiated | H.C. Wainwright | Buy |
Greenwich Lifesciences Inc Stock (GLSI) Latest News
Greenwich LifeSciences Provides Update on Corporate Events - GlobeNewswire
SINTX Technologies Announces Stock Repurchase Program - The Manila Times
Greenwich LifeSciences Expands Presence at Major Cancer & Healthcare Conferences | GLSI Stock News - StockTitan
Stocks Retreat As Bond Yields Climb On A Hawkish Fed - Barchart
Stocks Tumble as Hawkish Fed and Strong US Economic News Boosts Bond Yields - The Globe and Mail
Scoop Up Big Gains With 4 Stocks Witnessing Rise In Cash Flow - Barchart
Here Is What Could Be Next For Super Micro Computer As Deadline Gets Closer - Barchart
Stocks Tumble As Hawkish Fed And Strong US Economic News Boosts Bond Yields - Barchart
Stocks Retreat as Bond Yields Climb on a Hawkish Fed - The Globe and Mail
Applied Materials (AMAT-Q) QuotePress Release - The Globe and Mail
Greenwich LifeSciences Inc (GLSI) Quarterly 10-Q Report - Quartzy
Stocks Slip Ahead Of A Speech From Fed Chair Powell - Barchart
Stocks Close Lower On Hawkish Powell - Barchart
Greenwich LifeSciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Bell-Boeing Secures Contract To Aid CMV-22 Osprey Aircraft Program - Barchart
Best Momentum Stocks To Buy For November 14th - Barchart
Food Prices Worried Most Voters, But Trump's Plans Likely Won't Lower Their Grocery Bills - Barchart
Greenwich LifeSciences (NASDAQ:GLSI) Stock Price Down 1.6% – Time to Sell? - Defense World
Greenwich LifeSciences (NASDAQ:GLSI) Shares Down 1.6%What's Next? - MarketBeat
Stocks Climb And T-Note Yields Fall As US CPI Report Meets Expectations - Barchart
Stocks Slightly Lower As Indexes Consolidate Recent Rally - Barchart
Winners And Losers Of Q3: Texas Roadhouse (NASDAQ:TXRH) Vs The Rest Of The Sit-Down Dining Stocks - Barchart
Palantir Vs. SoundHound: Which AI Stock Has More Upside Potential? - Barchart
Time To Go Long Costco After The Stock Hits New Heights? - Barchart
My 2 Favorite Stocks That Investors Will Be Piling Into Next Year - Barchart
Rockwell Automation Q4 Earnings Beat Estimates, Revenues Dip Y/Y - Barchart
Small-Cap ETFs Set To Explode Under Trump Presidency - Barchart
Up 160% In 3 Months, Is It Too Late To Buy Astera Labs Stock? - Barchart
(GLSI) Trading Report - Stock Traders Daily
Form DEFA14A Greenwich LifeSciences, - StreetInsider.com
House Speaker Johnson Says GOP May Try To Repeal CHIPS Act, Then Walks It Back - Barchart
Root Stock Skyrockets 150% To Become Top Gainer On Q3 Profit And Revenue Surge: Retail Sentiment Soars - Barchart
Super Micro Stock Loses Nearly A Third Of Its Market Cap After Auditor EY Resigns: Retail Sentiment Nosedives - Barchart
Is DoorDash Stock A Good Buy Ahead Of Q3 Earnings? - Barchart
1 Outstanding AI Growth Stock To Grab Now - Barchart
CTLT Stock Falls As Potential Hindrance To NVO Buyout Deal Increases - Barchart
Greenwich LifeSciences (NASDAQ:GLSI) Stock Price Up 3.1%Here's What Happened - MarketBeat
(GLSI) On The My Stocks Page - Stock Traders Daily
Great week for Greenwich LifeSciences, Inc. (NASDAQ:GLSI) insiders who have 55% stake and they haven’t stopped buying - Simply Wall St
There's Reason For Concern Over OneSpaWorld Holdings Limited's (NASDAQ:OSW) Price - Simply Wall St
AUDUSD Elliott Wave Intraday Analysis - Barchart
S&P 500 Posts A Record High On Corporate Earnings Optimism - Barchart
(GLSI) Pivots Trading Plans and Risk Controls - Stock Traders Daily
What To Expect From RTX Corporation's Next Quarterly Earnings Report - Barchart
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Short Interest Update - Defense World
Public Sector Pension Investment Board Acquires 4,434 Shares of Worthington Steel, Inc. (NYSE:WS) - Defense World
Rhumbline Advisers Makes New Investment in Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Dollar’s Possible Breakout And Its Major Implications For Gold - Barchart
Greenwich LifeSciences CEO buys $21,945 in company stock - Investing.com India
Greenwich LifeSciences CEO buys $21,945 in company stock By Investing.com - Investing.com Australia
Insider Buying: Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Acquires 1,500 Shares of Stock - MarketBeat
Greenwich Lifesciences Inc Stock (GLSI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Greenwich Lifesciences Inc Stock (GLSI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Thompson Jaye | VP Clinical Reg Affairs |
Aug 12 '24 |
Buy |
13.85 |
800 |
11,080 |
263,148 |
| Patel Snehal | CEO and CFO |
Aug 06 '24 |
Buy |
13.81 |
2,000 |
27,620 |
5,534,602 |
| Patel Snehal | CEO and CFO |
Aug 05 '24 |
Buy |
13.18 |
5,500 |
72,490 |
5,532,602 |
| Thompson Jaye | VP Clinical Reg Affairs |
Aug 02 '24 |
Buy |
15.15 |
1,000 |
15,150 |
262,348 |
| Patel Snehal | CEO and CFO |
Jul 23 '24 |
Buy |
15.89 |
1,500 |
23,835 |
5,527,102 |
| Thompson Jaye | VP Clinical Reg Affairs |
Jul 18 '24 |
Buy |
16.00 |
1,000 |
16,000 |
261,348 |
| Patel Snehal | CEO and CFO |
Jun 13 '24 |
Buy |
14.30 |
174,825 |
2,499,998 |
5,525,602 |
| Patel Snehal | CEO and CFO |
Apr 01 '24 |
Buy |
19.08 |
3,000 |
57,240 |
5,350,777 |
| Patel Snehal | CEO and CFO |
Mar 22 '24 |
Buy |
19.98 |
2,500 |
49,950 |
5,347,777 |
| Patel Snehal | CEO and CFO |
Mar 20 '24 |
Buy |
17.68 |
1,500 |
26,520 |
5,345,277 |
0.42%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):